(E)-4-carboxystyryl-4-chlorobenzylsulfone, sodium salt: radioprotectant; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 23668369 |
| CHEMBL ID | 2219410 |
| SCHEMBL ID | 1195545 |
| MeSH ID | M0510541 |
| Synonym |
|---|
| on 01210.na |
| unii-1068sxu525 |
| recilisib sodium |
| (e)-4-carboxystyryl-4-chlorobenzylsulfone, sodium salt |
| ex-rad |
| 4-carboxystyryl-4-chlorobenzylsulfone |
| recilisib sodium [usan] |
| 922139-31-9 |
| 1068sxu525 , |
| on-01210.na |
| on 01210. na |
| CHEMBL2219410 |
| D10376 |
| recilisib sodium (usan) |
| sodium 4-((1e)-2-(((4-chlorophenyl)methyl)sulfonyl(ethenyl)benzoate |
| on-01210 sodium |
| recilisib sodium [who-dd] |
| SCHEMBL1195545 |
| Q5419119 |
| sodium;4-[(e)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]benzoate |
| EX-A2907 |
| DTXSID101336108 |
| HY-101625A |
| CS-0083716 |
| recilisib (sodium) |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Na showed relatively low bioavailability upon administration of the suspension formulation." | ( Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species. Chun, AW; Freshwater, RE; Gillum, AM; Maniar, M; Taft, DR, 2011) | 0.37 |
| " The goals of the study were to assess the comparative bioavailability of ON 01210." | ( Radioprotective effects of ON 01210.Na upon oral administration. Datta, K; Doiron, K; Fornace, AJ; Kumar, R; Maniar, M; Ren, C; Suman, S; Taft, DR, 2012) | 0.68 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " administration is being developed, in addition to an oral dosage form for potential use of the compound as a radioprotectant and a radiation-mitigating agent in wider military and civilian populations." | ( Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species. Chun, AW; Freshwater, RE; Gillum, AM; Maniar, M; Taft, DR, 2011) | 0.37 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1412330 | Radioprotective activity against 60Co gamma-irradiation-mediated cytotoxicity in HUVEC assessed as increase in survival rate at 40 uM preincubated for 24 hrs followed by gamma-irradiation and measured after 4 days by MTS assay relative to control | 2018 | MedChemComm, Apr-01, Volume: 9, Issue:4 | Synthesis and radioprotective effects of novel benzyl naphthyl sulfoxide (sulfone) derivatives transformed from Ex-RAD. |
| AID1412335 | Radioprotective activity against 60Co gamma-irradiation-induced toxicity in C57/BL mouse assessed as survival rate at 300 mg/kg, sc administered 15 mins and 24 hrs prior to irradiation and measured over 30 days post irradiation (Rvb = 50%) | 2018 | MedChemComm, Apr-01, Volume: 9, Issue:4 | Synthesis and radioprotective effects of novel benzyl naphthyl sulfoxide (sulfone) derivatives transformed from Ex-RAD. |
| AID1412329 | Radioprotective activity against 60Co gamma-irradiation-mediated cytotoxicity in HUVEC assessed as survival rate at 20 uM preincubated for 24 hrs followed by gamma-irradiation and measured after 4 days by MTS assay relative to control | 2018 | MedChemComm, Apr-01, Volume: 9, Issue:4 | Synthesis and radioprotective effects of novel benzyl naphthyl sulfoxide (sulfone) derivatives transformed from Ex-RAD. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||